Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Dec;15(6):848-53.
doi: 10.1007/s10157-011-0512-3. Epub 2011 Aug 9.

Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study

Akizuki Morikawa  1 , Kanaki Ishizeki, Yasunori Iwashima, Hiroki Yokoyama, Eiji Muto, Eiji Oshima, Masatomo Sekiguchi, Takanori Miura, Hiroshi Itoh, Masakazu Haneda
Affiliations
Randomized Controlled Trial

Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study

Akizuki Morikawa et al. Clin Exp Nephrol. 2011 Dec.

Abstract

Background: The aim of his study was to compare the efficacy of pioglitazone with metformin on the reduction of albuminuria in type 2 diabetic patients with hypertension and microalbuminuria treated with renin-angiotensin system inhibitors (RAS-Is).

Methods: The open-label, randomized trial was performed in type 2 diabetic patients with hypertension and microalbuminuria. On the basis of the treatment with RAS-Is, 68 patients with microalbuminuria received either pioglitazone (15-30 mg/day; n = 32) or metformin (500-750 mg/day; n = 31) for 52 weeks. Urinary albumin-to-creatinine ratio (UACR) was measured every 12 weeks.

Results: After 52 weeks of treatment, the changes in the log-UACR from baseline were -8.3% in the pioglitazone group and +4.2% in the metformin group (p = 0.01), with similar glycemic and blood pressure changes.

Conclusion: The combination of pioglitazone and RAS-Is showed therapeutic benefit in the reduction of urinary albumin excretion for type 2 diabetic patients with hypertension and microalbuminuria.

PubMed Disclaimer

References

    1. Diabetes Metab Res Rev. 2006 Sep-Oct;22(5):385-9 - PubMed
    1. Diabetes Care. 2007 Jun;30(6):1577-8 - PubMed
    1. Ren Fail. 2004 Sep;26(5):497-505 - PubMed
    1. Int J Cardiol. 2006 Feb 15;107(2):147-53 - PubMed
    1. Diabetes. 2005 Jul;54(7):2206-11 - PubMed

Publication types

MeSH terms

LinkOut - more resources